Transcription of 2020 Annual Report
{{id}} {{{paragraph}}}
2020 Annual ReportOur MissionTo discover, develop and deliver innovative medicines that help patients prevail over serious diseasesOur VisionTo be the world's leading biopharma company that transforms patients' lives through scienceOur ValuesIntegrity | Innovation | Urgency | Passion | Accountability | InclusionCover image: During a year when most of us were separated by the pandemic, our global collective efforts ensured that individual contributions came together to make a significant impact for Full-Year RevenuesGAAP Full-Year Change vs. Prior Year*63%Worldwide Revenues$ Forma Full-Year Change vs.
for thrombosis, cendakimab for eosinophilic esophagitis and CELMoDs for multiple myeloma. Our Research & Early Development teams are building a robust early pipeline across multiple platforms with more than 50 early-stage assets. We expect more than 20 experimental assets to progress through proof of concept in the next three years.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}